NDAORALTABLET
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ACCOLATE (zafirlukast) by PharmaIN is leukotriene receptor antagonists [moa]. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACCOLATE (zafirlukast) is an oral leukotriene receptor antagonist (LTRA) approved in 1996 for asthma management. It works by blocking cysteinyl leukotriene receptors, reducing airway inflammation and bronchoconstriction. The drug is indicated for prophylaxis and chronic treatment of asthma in adults and pediatric patients.
$0.008BPart D
LOE ApproachingDeclining
Minimal team expansion likely given LOE trajectory and modest Part D utilization; focus is on retention and managed decline.
Mechanism of Action
Leukotriene Receptor Antagonists
Pharmacologic Class:
Leukotriene Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
Started Dec 2025
12 enrolled
Allergy to Cats
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Started Dec 2007
44 enrolled
Healthy
Career Relevance
Working on ACCOLATE offers exposure to mature-market brand management and generic transition strategy, but limited upside for rapid career advancement or innovation-driven growth. This role is ideal for consolidation-focused professionals or those transitioning to higher-growth pipeline assets.
Worked on ACCOLATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.